Intellia Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Intellia Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and preparations for the 2027 commercial launch of its lead product candidate.
NASDAQ
DEFA14A: Intellia Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Intellia Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, and a new equity incentive plan.
NASDAQ
DEF 14A: Intellia Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals
Intellia Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, outlining proposals for director elections, auditor ratification, executive compensation, and a new equity incentive plan.
NASDAQ
Intellia Therapeutics will hold its annual stockholder meeting virtually on June 12, 2024, featuring proposals including the election of directors, ratification of auditors, executive compensation approval, and an amendment to limit officer liability.
NASDAQ
DEF 14A: Intellia Therapeutics Sets Date for 2024 Annual Stockholders Meeting, Outlines Key Proposals
Intellia Therapeutics will hold its 2024 Annual Meeting of Stockholders online on June 12, 2024, to vote on director elections, auditor ratification, executive compensation, and an amendment to limit officer liability.